{"id":68678,"date":"2026-06-22T20:23:13","date_gmt":"2026-06-22T12:23:13","guid":{"rendered":"https:\/\/flcube.com\/?p=68678"},"modified":"2026-06-22T20:23:14","modified_gmt":"2026-06-22T12:23:14","slug":"sanofis-sarclisa-subcutaneous-formulation-approved-in-japan-for-multiple-myeloma-across-treatment-settings","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=68678","title":{"rendered":"Sanofi&#8217;s Sarclisa Subcutaneous Formulation Approved in Japan for Multiple Myeloma Across Treatment Settings"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\"><strong>Sanofi<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/SNY:NASDAQ\">NASDAQ: SNY<\/a>) announced that Japan&#8217;s <strong>Ministry of Health, Labour and Welfare (MHLW)<\/strong> has approved the <strong>subcutaneous (SC) formulation<\/strong> of <strong>Sarclisa<\/strong> (isatuximab) for multiple myeloma treatment across both <strong>relapsed\/refractory (R\/R MM)<\/strong> and <strong>newly diagnosed (NDMM)<\/strong> settings. The approval marks Japan&#8217;s adoption of the innovative <strong>CirCLIQ on-body injector (OBI)<\/strong> delivery system, making Sarclisa SC the first anticancer therapy administered via this technology in the Japanese market.<\/p>\n\n\n\n<h2 id=\"h-regulatory-approval-details\" class=\"wp-block-heading\">Regulatory Approval Details<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Parameter<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Regulatory Agency<\/strong><\/td><td>MHLW (Japan)<\/td><\/tr><tr><td><strong>Product<\/strong><\/td><td>Sarclisa (isatuximab) subcutaneous formulation<\/td><\/tr><tr><td><strong>Delivery System<\/strong><\/td><td>CirCLIQ on-body injector (OBI)<\/td><\/tr><tr><td><strong>Approved Combinations<\/strong><\/td><td>\u2022 Pomalidomide + dexamethasone (Pd)<br>\u2022 Carfilzomib (for R\/R MM)<br>\u2022 Bortezomib + lenalidomide + dexamethasone (VRd) (for NDMM)<\/td><\/tr><tr><td><strong>Indications<\/strong><\/td><td>Relapsed\/refractory MM and newly diagnosed MM<\/td><\/tr><tr><td><strong>Approval Basis<\/strong><\/td><td>IRAKLIA Phase 3 study (NCT05405166) + supportive studies<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 id=\"h-clinical-evidence-amp-delivery-innovation\" class=\"wp-block-heading\">Clinical Evidence &amp; Delivery Innovation<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>IRAKLIA Phase 3 Study:<\/strong> Demonstrated <strong>non-inferiority<\/strong> of SC formulation compared to intravenous (IV) administration in R\/R MM patients<\/li>\n\n\n\n<li><strong>CirCLIQ Technology:<\/strong> First anticancer treatment globally to utilize the <strong>on-body injector system<\/strong>, reducing administration time from hours (IV) to minutes (SC)<\/li>\n\n\n\n<li><strong>Patient Convenience:<\/strong> Enables outpatient or at-home administration potential, significantly improving treatment experience and healthcare resource utilization<\/li>\n\n\n\n<li><strong>Global Validation:<\/strong> Previously approved in EU and UK, with Japan representing the first major Asian market adoption<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-market-impact-amp-strategic-significance\" class=\"wp-block-heading\">Market Impact &amp; Strategic Significance<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Japanese Myeloma Burden:<\/strong> Approximately <strong>7,500 new multiple myeloma cases annually<\/strong> in Japan, with aging population driving increased incidence<\/li>\n\n\n\n<li><strong>Treatment Paradigm Shift:<\/strong> SC formulation addresses significant unmet need for <strong>convenient, time-efficient administration<\/strong> in a disease requiring chronic therapy<\/li>\n\n\n\n<li><strong>Competitive Differentiation:<\/strong> Positions Sarclisa ahead of other anti-CD38 monoclonal antibodies (daratumumab) that remain IV-only in Japan<\/li>\n\n\n\n<li><strong>Commercial Expansion:<\/strong> Builds on Sarclisa&#8217;s existing presence in <strong>nearly 60 countries<\/strong> across four indications, strengthening Sanofi&#8217;s hematology franchise<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-global-myeloma-treatment-landscape\" class=\"wp-block-heading\">Global Myeloma Treatment Landscape<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">The approval reinforces the trend toward <strong>subcutaneous delivery<\/strong> in oncology, following successful transitions of other monoclonal antibodies from IV to SC formulations. Sanofi&#8217;s investment in the CirCLIQ platform demonstrates commitment to <strong>patient-centric innovation<\/strong> beyond molecule development alone.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">With multiple myeloma increasingly managed as a chronic condition requiring long-term therapy, administration convenience becomes a critical factor in treatment selection and patient adherence. The Japanese approval validates both the clinical equivalence and practical advantages of the SC formulation in a sophisticated, high-value market.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Forward-Looking Statements<\/strong><br>This brief contains forward-looking statements regarding regulatory approvals, market opportunities, and commercial expectations. Actual results may differ due to market dynamics, competitive pressures, and healthcare policy changes.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Sanofi (NASDAQ: SNY) announced that Japan&#8217;s Ministry of Health, Labour and Welfare (MHLW) has approved&#8230;<\/p>\n","protected":false},"author":1,"featured_media":68680,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_newsletter_access":"","_jetpack_dont_email_post_to_subs":false,"_jetpack_newsletter_tier_id":0,"_jetpack_memberships_contains_paywalled_content":false,"_jetpack_feature_clip_id":0,"_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2},"jetpack_post_was_ever_published":false},"categories":[7,11],"tags":[867,15,147],"class_list":["post-68678","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-drug","tag-nasdaq-sny","tag-product-approvals","tag-sanofi"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.5 (Yoast SEO v27.8) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Sanofi&#039;s Sarclisa Subcutaneous Formulation Approved in Japan for Multiple Myeloma Across Treatment Settings - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Sanofi (NASDAQ: SNY) announced that Japan&#039;s Ministry of Health, Labour and Welfare (MHLW) has approved the subcutaneous (SC) formulation of Sarclisa (isatuximab) for multiple myeloma treatment across both relapsed\/refractory (R\/R MM) and newly diagnosed (NDMM) settings. The approval marks Japan&#039;s adoption of the innovative CirCLIQ on-body injector (OBI) delivery system, making Sarclisa SC the first anticancer therapy administered via this technology in the Japanese market.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=68678\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Sanofi&#039;s Sarclisa Subcutaneous Formulation Approved in Japan for Multiple Myeloma Across Treatment Settings\" \/>\n<meta property=\"og:description\" content=\"Sanofi (NASDAQ: SNY) announced that Japan&#039;s Ministry of Health, Labour and Welfare (MHLW) has approved the subcutaneous (SC) formulation of Sarclisa (isatuximab) for multiple myeloma treatment across both relapsed\/refractory (R\/R MM) and newly diagnosed (NDMM) settings. The approval marks Japan&#039;s adoption of the innovative CirCLIQ on-body injector (OBI) delivery system, making Sarclisa SC the first anticancer therapy administered via this technology in the Japanese market.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=68678\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-06-22T12:23:13+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-06-22T12:23:14+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/06\/2203-1.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=68678#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=68678\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Sanofi&#8217;s Sarclisa Subcutaneous Formulation Approved in Japan for Multiple Myeloma Across Treatment Settings\",\"datePublished\":\"2026-06-22T12:23:13+00:00\",\"dateModified\":\"2026-06-22T12:23:14+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=68678\"},\"wordCount\":407,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=68678#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/06\\\/2203-1.webp\",\"keywords\":[\"NASDAQ: SNY\",\"Product approvals\",\"Sanofi\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=68678#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=68678\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=68678\",\"name\":\"Sanofi's Sarclisa Subcutaneous Formulation Approved in Japan for Multiple Myeloma Across Treatment Settings - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=68678#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=68678#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/06\\\/2203-1.webp\",\"datePublished\":\"2026-06-22T12:23:13+00:00\",\"dateModified\":\"2026-06-22T12:23:14+00:00\",\"description\":\"Sanofi (NASDAQ: SNY) announced that Japan's Ministry of Health, Labour and Welfare (MHLW) has approved the subcutaneous (SC) formulation of Sarclisa (isatuximab) for multiple myeloma treatment across both relapsed\\\/refractory (R\\\/R MM) and newly diagnosed (NDMM) settings. The approval marks Japan's adoption of the innovative CirCLIQ on-body injector (OBI) delivery system, making Sarclisa SC the first anticancer therapy administered via this technology in the Japanese market.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=68678#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=68678\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=68678#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/06\\\/2203-1.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/06\\\/2203-1.webp\",\"width\":1080,\"height\":608,\"caption\":\"Sanofi's Sarclisa Subcutaneous Formulation Approved in Japan for Multiple Myeloma Across Treatment Settings\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=68678#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Sanofi&#8217;s Sarclisa Subcutaneous Formulation Approved in Japan for Multiple Myeloma Across Treatment Settings\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Sanofi's Sarclisa Subcutaneous Formulation Approved in Japan for Multiple Myeloma Across Treatment Settings - Insight, China&#039;s Pharmaceutical Industry","description":"Sanofi (NASDAQ: SNY) announced that Japan's Ministry of Health, Labour and Welfare (MHLW) has approved the subcutaneous (SC) formulation of Sarclisa (isatuximab) for multiple myeloma treatment across both relapsed\/refractory (R\/R MM) and newly diagnosed (NDMM) settings. The approval marks Japan's adoption of the innovative CirCLIQ on-body injector (OBI) delivery system, making Sarclisa SC the first anticancer therapy administered via this technology in the Japanese market.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=68678","og_locale":"en_US","og_type":"article","og_title":"Sanofi's Sarclisa Subcutaneous Formulation Approved in Japan for Multiple Myeloma Across Treatment Settings","og_description":"Sanofi (NASDAQ: SNY) announced that Japan's Ministry of Health, Labour and Welfare (MHLW) has approved the subcutaneous (SC) formulation of Sarclisa (isatuximab) for multiple myeloma treatment across both relapsed\/refractory (R\/R MM) and newly diagnosed (NDMM) settings. The approval marks Japan's adoption of the innovative CirCLIQ on-body injector (OBI) delivery system, making Sarclisa SC the first anticancer therapy administered via this technology in the Japanese market.","og_url":"https:\/\/flcube.com\/?p=68678","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-06-22T12:23:13+00:00","article_modified_time":"2026-06-22T12:23:14+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/06\/2203-1.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=68678#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=68678"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Sanofi&#8217;s Sarclisa Subcutaneous Formulation Approved in Japan for Multiple Myeloma Across Treatment Settings","datePublished":"2026-06-22T12:23:13+00:00","dateModified":"2026-06-22T12:23:14+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=68678"},"wordCount":407,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=68678#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/06\/2203-1.webp","keywords":["NASDAQ: SNY","Product approvals","Sanofi"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=68678#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=68678","url":"https:\/\/flcube.com\/?p=68678","name":"Sanofi's Sarclisa Subcutaneous Formulation Approved in Japan for Multiple Myeloma Across Treatment Settings - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=68678#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=68678#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/06\/2203-1.webp","datePublished":"2026-06-22T12:23:13+00:00","dateModified":"2026-06-22T12:23:14+00:00","description":"Sanofi (NASDAQ: SNY) announced that Japan's Ministry of Health, Labour and Welfare (MHLW) has approved the subcutaneous (SC) formulation of Sarclisa (isatuximab) for multiple myeloma treatment across both relapsed\/refractory (R\/R MM) and newly diagnosed (NDMM) settings. The approval marks Japan's adoption of the innovative CirCLIQ on-body injector (OBI) delivery system, making Sarclisa SC the first anticancer therapy administered via this technology in the Japanese market.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=68678#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=68678"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=68678#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/06\/2203-1.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/06\/2203-1.webp","width":1080,"height":608,"caption":"Sanofi's Sarclisa Subcutaneous Formulation Approved in Japan for Multiple Myeloma Across Treatment Settings"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=68678#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Sanofi&#8217;s Sarclisa Subcutaneous Formulation Approved in Japan for Multiple Myeloma Across Treatment Settings"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/06\/2203-1.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/68678","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=68678"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/68678\/revisions"}],"predecessor-version":[{"id":68682,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/68678\/revisions\/68682"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/68680"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=68678"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=68678"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=68678"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}